Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
Trial details
- Registry ID
- NCT07704099
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Rinvatercept
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyNCT07704099 | KROS | Phase 2 | Recruiting | 2028-08-26Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |